Skip to main content
Top
Gepubliceerd in:

01-06-2019

Mapping the Strengths and Difficulties Questionnaire onto the Child Health Utility 9D in a large study of children

Auteurs: Rajan Sharma, Yuanyuan Gu, Kompal Sinha, Mona Aghdaee, Bonny Parkinson

Gepubliceerd in: Quality of Life Research | Uitgave 9/2019

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

Non-preference-based measures cannot be used to directly obtain utilities but can be converted to preference-based measures through mapping. The only mapping algorithm for estimating Child Health Utility-9D (CHU9D) utilities from Strengths and Difficulties Questionnaire (SDQ) responses has limitations. This study aimed to develop a more accurate algorithm.

Methods

We used a large sample of children (n = 6898), with negligible missing data, from the Longitudinal Study of Australian Children. Exploratory factor analysis (EFA) and Spearman’s rank correlation coefficients were used to assess conceptual overlap between SDQ and CHU9D. Direct mapping (involving seven regression methods) and response mapping (involving one regression method) approaches were considered. The final model was selected by ranking the performance of each method by averaging the following across tenfold cross-validation iterations: mean absolute error (MAE), mean squared error (MSE), and MAE and MSE for two subsamples where predicted utility values were < 0.50 (poor health) or > 0.90 (healthy). External validation was conducted using data from the Child and Adolescent Mental Health Services study.

Results

SDQ and CHU9D were moderately correlated (ρ = − 0.52, p < 0.001). EFA demonstrated that all CHU9D domains were associated with four SDQ subscales. The best-performing model was the Generalized Linear Model with SDQ items and gender as predictors (full sample MAE: 0.1149; MSE: 0.0227). The new algorithm performed well in the external validation.

Conclusions

The proposed mapping algorithm can produce robust estimates of CHU9D utilities from SDQ data for economic evaluations. Further research is warranted to assess the applicability of the algorithm among children with severe health problems.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Voetnoten
1
Utilities are measured on a cardinal scale, anchored at 0 (death) and 1 (full health) [1, 5, 9]. Utilities less than zero are possible if a health state is considered to be worse than death [1].
 
2
MAUIs are a health-related quality of life questionnaires which are associated with an algorithm to convert responses to the included questions into utilities.
 
3
Mapping is the process of establishing a statistical relationship between a non-PBM and a PBM using regression techniques.
 
4
It can certainly be updated using the new version of the CHU9D instrument but to our best knowledge such an updated algorithm is not publicly available. In this study we obtained a subsample of the original data used in Furber et al. [24] from the lead author and updated their algorithm to be used as a comparator of our new algorithm in the external validation.
 
5
For GLM and EEE the disutility was used as the outcome variable to avoid non-negative values.
 
6
Brant test was used to check proportional odds assumption to determine the ordered nature of CHU9D domains. Parallel assumption or proportional odds assumption is an assumption of an ordered logit model. This assumption assumes that coefficients between different categories of the dependent variable are equal.
 
7
The MAE was calculated as mean of the absolute values of the difference between the observed and predicted CHU9D utilities.
 
8
The MSE were computed as the mean squared differences between the predicted and observed CHU9D utilities.
 
9
Formula: \(\% \; {\text{Error}}\; {\text{for}}\;{\text{GMAE}} = 100 \times \frac{\text{MAE}}{{\left( {{\text{Max}}\left( {{\text{CHU}}9{\text{D}}\; {\text{utilities}}} \right) - {\text{Min}}\left( {{\text{CHU}}9{\text{D}}\; {\text{utilities}}} \right)} \right)}}.\)
 
10
Formula: \(\% \;{\text{Error}}\; {\text{for}}\; {\text{GMSE}} = 100 \times \frac{\text{MSE}}{{\left( {{\text{Max}}\left( {{\text{CHU}}9{\text{D}}\;{\text{utilities}}} \right) - {\text{Min}}\left( {{\text{CHU}}9{\text{D }}\;{\text{utilities}}} \right)} \right)}}.\)
Note: \(\left( {{\text{Max}}\left( {{\text{CHU}}9{\text{D}}\;{\text{utilities}}} \right)} \right) = 1\;\;{\text{and}}\;\;\left( {{\text{Min}}\left( {{\text{CHU}}9{\text{D}}\;{\text{utilities}}} \right)} \right) = - \,0.1059\)
 
11
We used new CHU9D tariff to obtain observed CHU9D variable in the CAMHS dataset, ran an OLS regression with SDQ subscales as predictors and obtained coefficients to be used as new or modified mapping algorithm for Furber et al.
 
Literatuur
1.
go back to reference Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. (2015). Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press. Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. (2015). Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press.
2.
go back to reference Canadian Agency for Drugs Technologies in Health. (2006). Guidelines for economic evaluation of pharmaceuticals: Canada. Ottawa: Canadian Agency for Drugs and Technologies in Health. Canadian Agency for Drugs Technologies in Health. (2006). Guidelines for economic evaluation of pharmaceuticals: Canada. Ottawa: Canadian Agency for Drugs and Technologies in Health.
3.
go back to reference National Institute for Health and Clinical Excellence. (2013). Guide to the methods of technology appraisal 2013. National Institute for Health and Clinical Excellence. (2013). Guide to the methods of technology appraisal 2013.
4.
go back to reference Pharmaceutical Benefits Advisory Committee. (2016). Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee (version 5.0). Australian Government Department of Health. Pharmaceutical Benefits Advisory Committee. (2016). Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee (version 5.0). Australian Government Department of Health.
6.
go back to reference Brazier, J. E., Yang, Y., Tsuchiya, A., & Rowen, D. L. (2010). A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. The European Journal of Health Economics, 11(2), 215–225.PubMedCrossRef Brazier, J. E., Yang, Y., Tsuchiya, A., & Rowen, D. L. (2010). A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. The European Journal of Health Economics, 11(2), 215–225.PubMedCrossRef
7.
go back to reference Harris, A. H., Hill, S. R., Chin, G., Li, J. J., & Walkom, E. (2008). The role of value for money in public insurance coverage decisions for drugs in Australia: A retrospective analysis 1994–2004. Medical Decision Making, 28(5), 713–722.PubMedCrossRef Harris, A. H., Hill, S. R., Chin, G., Li, J. J., & Walkom, E. (2008). The role of value for money in public insurance coverage decisions for drugs in Australia: A retrospective analysis 1994–2004. Medical Decision Making, 28(5), 713–722.PubMedCrossRef
8.
go back to reference Neumann, P. J., Cohen, J. T., & Weinstein, M. C. (2014). Updating cost-effectiveness—The curious resilience of the $50,000-per-QALY threshold. New England Journal of Medicine, 371(9), 796–797.PubMedCrossRef Neumann, P. J., Cohen, J. T., & Weinstein, M. C. (2014). Updating cost-effectiveness—The curious resilience of the $50,000-per-QALY threshold. New England Journal of Medicine, 371(9), 796–797.PubMedCrossRef
9.
10.
go back to reference Tolley, K. (2009). What are health utilities. London: Hayward Medical Communications. Tolley, K. (2009). What are health utilities. London: Hayward Medical Communications.
11.
go back to reference Torrance, G. W. (1987). Utility approach to measuring health-related quality of life. Journal of Chronic Diseases, 40(6), 593–600.PubMedCrossRef Torrance, G. W. (1987). Utility approach to measuring health-related quality of life. Journal of Chronic Diseases, 40(6), 593–600.PubMedCrossRef
12.
13.
go back to reference Shaw, J. W., Johnson, J. A., & Coons, S. J. (2005). US valuation of the EQ-5D health states: Development and testing of the D1 valuation model. Medical Care, 43, 203–220.PubMedCrossRef Shaw, J. W., Johnson, J. A., & Coons, S. J. (2005). US valuation of the EQ-5D health states: Development and testing of the D1 valuation model. Medical Care, 43, 203–220.PubMedCrossRef
14.
go back to reference Brazier, J., Roberts, J., & Deverill, M. (2002). The estimation of a preference-based measure of health from the SF-36. Journal of Health Economics, 21(2), 271–292.PubMedCrossRef Brazier, J., Roberts, J., & Deverill, M. (2002). The estimation of a preference-based measure of health from the SF-36. Journal of Health Economics, 21(2), 271–292.PubMedCrossRef
15.
go back to reference Brazier, J. E., & Roberts, J. (2004). The estimation of a preference-based measure of health from the SF-12. Medical Care, 42(9), 851–859.PubMedCrossRef Brazier, J. E., & Roberts, J. (2004). The estimation of a preference-based measure of health from the SF-12. Medical Care, 42(9), 851–859.PubMedCrossRef
16.
go back to reference Torrance, G. W. (1976). Social preferences for health states: An empirical evaluation of three measurement techniques. Socio-economic Planning Sciences, 10(3), 129–136.CrossRef Torrance, G. W. (1976). Social preferences for health states: An empirical evaluation of three measurement techniques. Socio-economic Planning Sciences, 10(3), 129–136.CrossRef
17.
go back to reference Farquhar, P. H. (1984). State of the art—Utility assessment methods. Management Science, 30(11), 1283–1300.CrossRef Farquhar, P. H. (1984). State of the art—Utility assessment methods. Management Science, 30(11), 1283–1300.CrossRef
18.
go back to reference Kontodimopoulos, N., Argiriou, M., Theakos, N., & Niakas, D. (2011). The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure. The European Journal of Health Economics, 12(4), 383–391.PubMedCrossRef Kontodimopoulos, N., Argiriou, M., Theakos, N., & Niakas, D. (2011). The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure. The European Journal of Health Economics, 12(4), 383–391.PubMedCrossRef
19.
go back to reference Kularatna, S., Byrnes, J., Chan, Y. K., Carrington, M. J., Stewart, S., & Scuffham, P. A. (2017). Comparison of contemporaneous responses for EQ-5D-3L and Minnesota living with heart failure: A case for disease specific multiattribute utility instrument in cardiovascular conditions. International Journal of Cardiology, 227, 172–176.PubMedCrossRef Kularatna, S., Byrnes, J., Chan, Y. K., Carrington, M. J., Stewart, S., & Scuffham, P. A. (2017). Comparison of contemporaneous responses for EQ-5D-3L and Minnesota living with heart failure: A case for disease specific multiattribute utility instrument in cardiovascular conditions. International Journal of Cardiology, 227, 172–176.PubMedCrossRef
20.
go back to reference Wailoo, A. J., Hernandez-Alava, M., Manca, A., Mejia, A., Ray, J., Crawford, B., et al. (2017). Mapping to estimate health-state utility from non-preference-based outcome measures: An ISPOR good practices for outcomes research task force report. Value in Health, 20(1), 18–27.PubMedCrossRef Wailoo, A. J., Hernandez-Alava, M., Manca, A., Mejia, A., Ray, J., Crawford, B., et al. (2017). Mapping to estimate health-state utility from non-preference-based outcome measures: An ISPOR good practices for outcomes research task force report. Value in Health, 20(1), 18–27.PubMedCrossRef
21.
go back to reference Calxton, K., Martin, S., Soares, M., Rice, N., Spackman, E., Hinde, S., et al. (2013). Methods for the estimation of the NICE cost effectiveness threshold. New York: Centre for Health Economics, University of York. Calxton, K., Martin, S., Soares, M., Rice, N., Spackman, E., Hinde, S., et al. (2013). Methods for the estimation of the NICE cost effectiveness threshold. New York: Centre for Health Economics, University of York.
22.
go back to reference Committee, Pharmaceutical Benefits Advisory. (2016). Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (PBAC). Version 5.0. Canberra: Department of Health. Committee, Pharmaceutical Benefits Advisory. (2016). Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (PBAC). Version 5.0. Canberra: Department of Health.
23.
go back to reference Kearns, B., Ara, R., Wailoo, A., Manca, A., Alava, M. H., Abrams, K., et al. (2013). Good practice guidelines for the use of statistical regression models in economic evaluations. Pharmacoeconomics, 31(8), 643–652.PubMedCrossRef Kearns, B., Ara, R., Wailoo, A., Manca, A., Alava, M. H., Abrams, K., et al. (2013). Good practice guidelines for the use of statistical regression models in economic evaluations. Pharmacoeconomics, 31(8), 643–652.PubMedCrossRef
24.
go back to reference Furber, G., Segal, L., Leach, M., & Cocks, J. (2014). Mapping scores from the strengths and difficulties questionnaire (SDQ) to preference-based utility values. Quality of Life Research, 23(2), 403–411.PubMedCrossRef Furber, G., Segal, L., Leach, M., & Cocks, J. (2014). Mapping scores from the strengths and difficulties questionnaire (SDQ) to preference-based utility values. Quality of Life Research, 23(2), 403–411.PubMedCrossRef
25.
go back to reference Ratcliffe, J., Flynn, T., Terlich, F., Stevens, K., Brazier, J., & Sawyer, M. (2012). Developing adolescent-specific health state values for economic evaluation. Pharmacoeconomics, 30(8), 713–727.PubMedCrossRef Ratcliffe, J., Flynn, T., Terlich, F., Stevens, K., Brazier, J., & Sawyer, M. (2012). Developing adolescent-specific health state values for economic evaluation. Pharmacoeconomics, 30(8), 713–727.PubMedCrossRef
26.
go back to reference Gray, L. A., Alava, M. H., & Wailoo, A. J. (2017). Development of methods for the mapping of utilities using mixture models: Mapping the AQLQ-S to the EQ-5D-5L and the HUI3 in patients with asthma. Value in Health, 21(6), 748–757.PubMedCrossRef Gray, L. A., Alava, M. H., & Wailoo, A. J. (2017). Development of methods for the mapping of utilities using mixture models: Mapping the AQLQ-S to the EQ-5D-5L and the HUI3 in patients with asthma. Value in Health, 21(6), 748–757.PubMedCrossRef
27.
go back to reference Varni, J. W., Burwinkle, T. M., & Lane, M. M. (2005). Health-related quality of life measurement in pediatric clinical practice: An appraisal and precept for future research and application. Health and Quality of Life Outcomes, 3(1), 34.PubMedPubMedCentralCrossRef Varni, J. W., Burwinkle, T. M., & Lane, M. M. (2005). Health-related quality of life measurement in pediatric clinical practice: An appraisal and precept for future research and application. Health and Quality of Life Outcomes, 3(1), 34.PubMedPubMedCentralCrossRef
28.
go back to reference Edwards, B. (2014). Growing up in Australia: The longitudinal study of Australian children: Entering adolescence and becoming a young adult. Family Matters, 95, 5. Edwards, B. (2014). Growing up in Australia: The longitudinal study of Australian children: Entering adolescence and becoming a young adult. Family Matters, 95, 5.
29.
go back to reference Bennett, D. A. (2001). How can I deal with missing data in my study? Australian and New Zealand Journal of Public Health, 25(5), 464–469.PubMedCrossRef Bennett, D. A. (2001). How can I deal with missing data in my study? Australian and New Zealand Journal of Public Health, 25(5), 464–469.PubMedCrossRef
30.
go back to reference Schafer, J. L. (1999). Multiple imputation: A primer. Statistical Methods in Medical Research, 8(1), 3–15.PubMedCrossRef Schafer, J. L. (1999). Multiple imputation: A primer. Statistical Methods in Medical Research, 8(1), 3–15.PubMedCrossRef
31.
go back to reference Refaeilzadeh, P., Tang, L., & Liu, H. (2016). Cross-validation. Encyclopedia of database systems (pp. 1–7). Boston: Springer. Refaeilzadeh, P., Tang, L., & Liu, H. (2016). Cross-validation. Encyclopedia of database systems (pp. 1–7). Boston: Springer.
32.
go back to reference Goodman, R. (1997). The strengths and difficulties questionnaire: A research note. Journal of Child Psychology and Psychiatry, 38(5), 581–586.PubMedCrossRef Goodman, R. (1997). The strengths and difficulties questionnaire: A research note. Journal of Child Psychology and Psychiatry, 38(5), 581–586.PubMedCrossRef
33.
go back to reference Stevens, K. (2011). Assessing the performance of a new generic measure of health-related quality of life for children and refining it for use in health state valuation. Applied Health Economics and Health Policy, 9(3), 157–169.PubMedCrossRef Stevens, K. (2011). Assessing the performance of a new generic measure of health-related quality of life for children and refining it for use in health state valuation. Applied Health Economics and Health Policy, 9(3), 157–169.PubMedCrossRef
34.
go back to reference Stevens, K. (2009). Developing a descriptive system for a new preference-based measure of health-related quality of life for children. Quality of Life Research, 18(8), 1105–1113.PubMedCrossRef Stevens, K. (2009). Developing a descriptive system for a new preference-based measure of health-related quality of life for children. Quality of Life Research, 18(8), 1105–1113.PubMedCrossRef
35.
go back to reference StataCorp. (2017). Stata statistical software: Release 15. College Station, TX: StataCorp LLC. StataCorp. (2017). Stata statistical software: Release 15. College Station, TX: StataCorp LLC.
36.
go back to reference Petrou, S., Rivero-Arias, O., Dakin, H., Longworth, L., Oppe, M., Froud, R., et al. (2015). The MAPS reporting statement for studies mapping onto generic preference-based outcome measures: Explanation and elaboration. Pharmacoeconomics, 33(10), 993–1011.PubMedCrossRef Petrou, S., Rivero-Arias, O., Dakin, H., Longworth, L., Oppe, M., Froud, R., et al. (2015). The MAPS reporting statement for studies mapping onto generic preference-based outcome measures: Explanation and elaboration. Pharmacoeconomics, 33(10), 993–1011.PubMedCrossRef
37.
go back to reference Tosh, J. C., Longworth, L. J., & George, E. (2011). Utility values in National Institute for Health and Clinical Excellence (NICE) technology appraisals. Value in Health, 14(1), 102–109.PubMedCrossRef Tosh, J. C., Longworth, L. J., & George, E. (2011). Utility values in National Institute for Health and Clinical Excellence (NICE) technology appraisals. Value in Health, 14(1), 102–109.PubMedCrossRef
38.
go back to reference Round, J., & Hawton, A. (2017). Statistical alchemy: Conceptual validity and mapping to generate health state utility values. PharmacoEconomics-Open, 1(4), 233–239.PubMedPubMedCentralCrossRef Round, J., & Hawton, A. (2017). Statistical alchemy: Conceptual validity and mapping to generate health state utility values. PharmacoEconomics-Open, 1(4), 233–239.PubMedPubMedCentralCrossRef
39.
go back to reference Schroeder, M. A., Lander, J., & Levine-Silverman, S. (1990). Diagnosing and dealing with multicollinearity. Western Journal of Nursing Research, 12(2), 175–187.PubMedCrossRef Schroeder, M. A., Lander, J., & Levine-Silverman, S. (1990). Diagnosing and dealing with multicollinearity. Western Journal of Nursing Research, 12(2), 175–187.PubMedCrossRef
40.
go back to reference Dziuban, C. D., & Shirkey, E. C. (1974). When is a correlation matrix appropriate for factor analysis? Some decision rules. Psychological Bulletin, 81(6), 358.CrossRef Dziuban, C. D., & Shirkey, E. C. (1974). When is a correlation matrix appropriate for factor analysis? Some decision rules. Psychological Bulletin, 81(6), 358.CrossRef
41.
go back to reference Tobias, S., & Carlson, J. E. (1969). Brief report: Bartlett’s test of sphericity and chance findings in factor analysis. Multivariate Behavioral Research, 4(3), 375–377.PubMedCrossRef Tobias, S., & Carlson, J. E. (1969). Brief report: Bartlett’s test of sphericity and chance findings in factor analysis. Multivariate Behavioral Research, 4(3), 375–377.PubMedCrossRef
42.
go back to reference Brown, J. (2001). What is an eigenvalue? JALT Testing & Evaluation SIG Newsletter, 5(1), 15–19. Brown, J. (2001). What is an eigenvalue? JALT Testing & Evaluation SIG Newsletter, 5(1), 15–19.
43.
go back to reference Izquierdo, I., Olea, J., & Abad, F. J. (2014). Exploratory factor analysis in validation studies: Uses and recommendations. Psicothema, 26(3), 395–400.PubMed Izquierdo, I., Olea, J., & Abad, F. J. (2014). Exploratory factor analysis in validation studies: Uses and recommendations. Psicothema, 26(3), 395–400.PubMed
44.
go back to reference Wooldridge, J. M. (2010). Econometric analysis of cross section and panel data. London: MIT Press. Wooldridge, J. M. (2010). Econometric analysis of cross section and panel data. London: MIT Press.
45.
go back to reference Nelder, J. A., & Baker, R. J. (2004). Generalized linear models. Encyclopedia of Statistical Sciences. New York: Wiley. Nelder, J. A., & Baker, R. J. (2004). Generalized linear models. Encyclopedia of Statistical Sciences. New York: Wiley.
46.
go back to reference Masyn, K., Nathan, P., & Little, T. (2013). The Oxford handbook of quantitative methods. Statistical analysis (Vol. 2). Oxford: Oxford University Press. Masyn, K., Nathan, P., & Little, T. (2013). The Oxford handbook of quantitative methods. Statistical analysis (Vol. 2). Oxford: Oxford University Press.
47.
go back to reference Manning, W. G., & Mullahy, J. (2001). Estimating log models: To transform or not to transform? Journal of Health Economics, 20(4), 461–494.PubMedCrossRef Manning, W. G., & Mullahy, J. (2001). Estimating log models: To transform or not to transform? Journal of Health Economics, 20(4), 461–494.PubMedCrossRef
48.
go back to reference Pregibon, D. (1980). Goodness of link tests for generalized linear models. Applied Statistics, 29, 14–15.CrossRef Pregibon, D. (1980). Goodness of link tests for generalized linear models. Applied Statistics, 29, 14–15.CrossRef
49.
go back to reference Pearson, E., & Please, N. (1975). Relation between the shape of population distribution and the robustness of four simple test statistics. Biometrika, 62(2), 223–241.CrossRef Pearson, E., & Please, N. (1975). Relation between the shape of population distribution and the robustness of four simple test statistics. Biometrika, 62(2), 223–241.CrossRef
50.
go back to reference Hosmer, D. W., Jr., Lemeshow, S., & Sturdivant, R. X. (2013). Applied logistic regression (Vol. 398). New York: Wiley.CrossRef Hosmer, D. W., Jr., Lemeshow, S., & Sturdivant, R. X. (2013). Applied logistic regression (Vol. 398). New York: Wiley.CrossRef
51.
go back to reference Glick, H. A., Doshi, J. A., Sonnad, S. S., & Polsky, D. (2014). Economic evaluation in clinical trials. Oxford: Oxford University Press.CrossRef Glick, H. A., Doshi, J. A., Sonnad, S. S., & Polsky, D. (2014). Economic evaluation in clinical trials. Oxford: Oxford University Press.CrossRef
52.
go back to reference Basu, A. (2005). Extended generalized linear models: Simultaneous estimation of flexible link and variance functions. Stata Journal, 5(4), 501.CrossRef Basu, A. (2005). Extended generalized linear models: Simultaneous estimation of flexible link and variance functions. Stata Journal, 5(4), 501.CrossRef
53.
go back to reference Swearingen, C. J., Castro, M. M., & Bursac, Z. (2012). Inflated beta regression: Zero, one and everything in between. In: SAS global forum, 2012 (pp. 1–11) Swearingen, C. J., Castro, M. M., & Bursac, Z. (2012). Inflated beta regression: Zero, one and everything in between. In: SAS global forum, 2012 (pp. 1–11)
54.
go back to reference McDonald, J. F., & Moffitt, R. A. (1980). The uses of Tobit analysis. The Review of Economics and Statistics, 62, 318–321.CrossRef McDonald, J. F., & Moffitt, R. A. (1980). The uses of Tobit analysis. The Review of Economics and Statistics, 62, 318–321.CrossRef
55.
go back to reference Longworth, L., Yang, Y., Young, T., Mulhern, B., Hernandez Alava, M., Mukuria, C., et al. (2014). Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: A systematic review, statistical modelling and survey. Health Technology Assessment, 18, 1–224.PubMedCrossRef Longworth, L., Yang, Y., Young, T., Mulhern, B., Hernandez Alava, M., Mukuria, C., et al. (2014). Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: A systematic review, statistical modelling and survey. Health Technology Assessment, 18, 1–224.PubMedCrossRef
56.
go back to reference Brennan, D. S., & Spencer, A. J. (2006). Mapping oral health related quality of life to generic health state values. BMC Health Services Research, 6(1), 96.PubMedPubMedCentralCrossRef Brennan, D. S., & Spencer, A. J. (2006). Mapping oral health related quality of life to generic health state values. BMC Health Services Research, 6(1), 96.PubMedPubMedCentralCrossRef
57.
go back to reference Powell, J. L. (1984). Least absolute deviations estimation for the censored regression model. Journal of Econometrics, 25(3), 303–325.CrossRef Powell, J. L. (1984). Least absolute deviations estimation for the censored regression model. Journal of Econometrics, 25(3), 303–325.CrossRef
58.
go back to reference Sullivan, P. W., & Ghushchyan, V. (2006). Mapping the EQ-5D index from the SF-12: US general population preferences in a nationally representative sample. Medical Decision Making, 26(4), 401–409.PubMedPubMedCentralCrossRef Sullivan, P. W., & Ghushchyan, V. (2006). Mapping the EQ-5D index from the SF-12: US general population preferences in a nationally representative sample. Medical Decision Making, 26(4), 401–409.PubMedPubMedCentralCrossRef
59.
go back to reference McLachlan, G., & Peel, D. (2004). Finite mixture models. New York: Wiley. McLachlan, G., & Peel, D. (2004). Finite mixture models. New York: Wiley.
60.
go back to reference Alava, M. H., Wailoo, A. J., & Ara, R. (2012). Tails from the peak district: Adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value in Health, 15(3), 550–561.CrossRef Alava, M. H., Wailoo, A. J., & Ara, R. (2012). Tails from the peak district: Adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value in Health, 15(3), 550–561.CrossRef
61.
go back to reference Hernandez Alava, M., & Wailoo, A. (2015). Fitting adjusted limited dependent variable mixture models to EQ-5D. Stata Journal, 15(3), 737–750.CrossRef Hernandez Alava, M., & Wailoo, A. (2015). Fitting adjusted limited dependent variable mixture models to EQ-5D. Stata Journal, 15(3), 737–750.CrossRef
62.
go back to reference Grun, B., & Leisch, F. (2008). FlexMix version 2: Finite mixtures with concomitant variables and varying and constant parameters. Journal of Statistical Software, 28(4), 1–35.CrossRef Grun, B., & Leisch, F. (2008). FlexMix version 2: Finite mixtures with concomitant variables and varying and constant parameters. Journal of Statistical Software, 28(4), 1–35.CrossRef
63.
go back to reference Ratcliffe, J., Huynh, E., Chen, G., Stevens, K., Swait, J., Brazier, J., et al. (2016). Valuing the Child Health Utility 9D: Using profile case best worst scaling methods to develop a new adolescent specific scoring algorithm. Social Science and Medicine, 157, 48–59.PubMedCrossRef Ratcliffe, J., Huynh, E., Chen, G., Stevens, K., Swait, J., Brazier, J., et al. (2016). Valuing the Child Health Utility 9D: Using profile case best worst scaling methods to develop a new adolescent specific scoring algorithm. Social Science and Medicine, 157, 48–59.PubMedCrossRef
64.
go back to reference Le, Q. A., & Doctor, J. N. (2011). Probabilistic mapping of descriptive health status responses onto health state utilities using Bayesian networks: An empirical analysis converting SF-12 into EQ-5D utility index in a national US sample. Medical Care, 49, 451–460.PubMedCrossRef Le, Q. A., & Doctor, J. N. (2011). Probabilistic mapping of descriptive health status responses onto health state utilities using Bayesian networks: An empirical analysis converting SF-12 into EQ-5D utility index in a national US sample. Medical Care, 49, 451–460.PubMedCrossRef
65.
go back to reference Gray, A. M., Rivero-Arias, O., & Clarke, P. M. (2006). Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Medical Decision Making, 26(1), 18–29.PubMedCrossRef Gray, A. M., Rivero-Arias, O., & Clarke, P. M. (2006). Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Medical Decision Making, 26(1), 18–29.PubMedCrossRef
66.
go back to reference Steyerberg, E. (2009). Validation of prediction models. Clinical prediction models (pp. 299–311). Berlin: Springer.CrossRef Steyerberg, E. (2009). Validation of prediction models. Clinical prediction models (pp. 299–311). Berlin: Springer.CrossRef
67.
go back to reference Kaiser, H. F., & Rice, J. (1974). Little jiffy, mark IV. Educational and Psychological Measurement, 34(1), 111–117.CrossRef Kaiser, H. F., & Rice, J. (1974). Little jiffy, mark IV. Educational and Psychological Measurement, 34(1), 111–117.CrossRef
68.
go back to reference Collado-Mateo, D., Chen, G., Garcia-Gordillo, M. A., Iezzi, A., Adsuar, J. C., Olivares, P. R., et al. (2017). Fibromyalgia and quality of life: Mapping the revised fibromyalgia impact questionnaire to the preference-based instruments. Health and Quality of Life Outcomes, 15(1), 114.PubMedPubMedCentralCrossRef Collado-Mateo, D., Chen, G., Garcia-Gordillo, M. A., Iezzi, A., Adsuar, J. C., Olivares, P. R., et al. (2017). Fibromyalgia and quality of life: Mapping the revised fibromyalgia impact questionnaire to the preference-based instruments. Health and Quality of Life Outcomes, 15(1), 114.PubMedPubMedCentralCrossRef
69.
go back to reference Teckle, P., McTaggart-Cowan, H., Van der Hoek, K., Chia, S., Melosky, B., Gelmon, K., et al. (2013). Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D. Health and Quality of Life Outcomes, 11(1), 203.PubMedPubMedCentralCrossRef Teckle, P., McTaggart-Cowan, H., Van der Hoek, K., Chia, S., Melosky, B., Gelmon, K., et al. (2013). Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D. Health and Quality of Life Outcomes, 11(1), 203.PubMedPubMedCentralCrossRef
70.
go back to reference Kay, S., Tolley, K., Colayco, D., Khalaf, K., Anderson, P., & Globe, D. (2013). Mapping EQ-5D utility scores from the Incontinence Quality of Life Questionnaire among patients with neurogenic and idiopathic overactive bladder. Value in Health, 16(2), 394–402.PubMedCrossRef Kay, S., Tolley, K., Colayco, D., Khalaf, K., Anderson, P., & Globe, D. (2013). Mapping EQ-5D utility scores from the Incontinence Quality of Life Questionnaire among patients with neurogenic and idiopathic overactive bladder. Value in Health, 16(2), 394–402.PubMedCrossRef
71.
go back to reference Jones, A. M., Lomas, J., Moore, P., & Rice, N. (2013). A quasi-Monte Carlo comparison of developments in parametric and semi-parametric regression methods for heavy tailed and non-normal data: With an application to healthcare costs. Health Econometrics and Data Group Working Paper, 13, 30. Jones, A. M., Lomas, J., Moore, P., & Rice, N. (2013). A quasi-Monte Carlo comparison of developments in parametric and semi-parametric regression methods for heavy tailed and non-normal data: With an application to healthcare costs. Health Econometrics and Data Group Working Paper, 13, 30.
72.
go back to reference Lamu, A. N., & Olsen, J. A. (2018). Testing alternative regression models to predict utilities: Mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D. Quality of Life Research, 27(11), 2823–2839.PubMedCrossRef Lamu, A. N., & Olsen, J. A. (2018). Testing alternative regression models to predict utilities: Mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D. Quality of Life Research, 27(11), 2823–2839.PubMedCrossRef
73.
go back to reference Rowen, D., Brazier, J., & Roberts, J. (2009). Mapping SF-36 onto the EQ-5D index: How reliable is the relationship? Health and Quality of Life Outcomes, 7(1), 27.PubMedPubMedCentralCrossRef Rowen, D., Brazier, J., & Roberts, J. (2009). Mapping SF-36 onto the EQ-5D index: How reliable is the relationship? Health and Quality of Life Outcomes, 7(1), 27.PubMedPubMedCentralCrossRef
74.
go back to reference Goldsmith, K. A., Dyer, M. T., Buxton, M. J., & Sharples, L. D. (2010). Mapping of the EQ-5D index from clinical outcome measures and demographic variables in patients with coronary heart disease. Health and Quality of Life Outcomes, 8(1), 54.PubMedPubMedCentralCrossRef Goldsmith, K. A., Dyer, M. T., Buxton, M. J., & Sharples, L. D. (2010). Mapping of the EQ-5D index from clinical outcome measures and demographic variables in patients with coronary heart disease. Health and Quality of Life Outcomes, 8(1), 54.PubMedPubMedCentralCrossRef
Metagegevens
Titel
Mapping the Strengths and Difficulties Questionnaire onto the Child Health Utility 9D in a large study of children
Auteurs
Rajan Sharma
Yuanyuan Gu
Kompal Sinha
Mona Aghdaee
Bonny Parkinson
Publicatiedatum
01-06-2019
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 9/2019
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-019-02220-x

Andere artikelen Uitgave 9/2019

Quality of Life Research 9/2019 Naar de uitgave